PCN69 QUALITY OF LIFE IMPACT OF HOT FLUSHES IN MEN RECEIVING TREATMENT FOR PROSTATE CANCER  by Nixon, A et al.
variables (age, marital status, education, employment, income,
comorbidity), older age, widowhood, lower education, retire-
ment, and comorbidity (Charlson > 2), were associated with
lower QoL (all p < 0.05). In multivariate analyses, all patient-
related variables explained 18–21% of the variance in scores.
With the addition of disease-related variables (treatment with
radical prostatectomy, radiation, or hormones; metastases,
Gleason score at diagnosis), the model explained 21–25% of the
variance. Patients currently on hormone treatment had lower
PORPUS-Ui and HUI3 scores than patients treated with hor-
mones in the past or never (p < 0.05). System-related variables
(year and county of diagnosis) contributed little to the explained
variance (1–3%). Symptom-related variables (PCI urinary,
sexual, bowel function) were the strongest predictors of QOL
(explaining 47–70% of the variance). CONCLUSION: Symp-
toms related to PC and its treatment have large effects on the
QoL of PC survivors. Although many variables are associated
with QoL, only prostate symptoms and comorbidity have inde-
pendent effects.
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OBJECTIVE: A multicenter phase III trial showed patients with
stage III or IV follicular lymphoma who achieved a partial or
complete remission after ﬁrst-line treatment receiving 90Y-
ibritumomab tiuxetan had signiﬁcantly longer PFS time as com-
pared to similar patients receiving no treatment. The objective of
this study was to determine the impact of 90Y-ibritumomab
tiuxetan on health-related quality of life. METHODS: Health-
related quality of life was assessed using EORTC QLQ-C30
version 2 and EuroQoL-5D (EQ-5D) questionnaires. These ques-
tionnaires were administered at screening, week 14 and every 6
months thereafter and ﬁnally at end of follow-up. Descriptive
statistics were used to compare scores across treatment groups.
The change in scores from baseline was also assessed by gender,
age and ﬁrst-line treatment. Mixed effects model was used to
assess the factors that were associated with ﬁnal scores of Visual
Analogue Scale (VAS) of EQ-5D.RESULTS:Nonotable treatment
differences were observed in the scores of EORTC QLQ-C30 (all
domains) scores across timepoints or changes from baseline. This
result was true for all sub-groups. The mean scores for EQ-5D at
screening and ﬁnal visit were 0.83 and 0.84 for 90Y-ibritumomab
tiuxetan and 0.84 and 0.83 for control arm. The mean VAS scores
at screening and ﬁnal visit were 77.52 and 77.64 for 90Y-
ibritumomab tiuxetan and 76.57 and 78.51 for control arm. An
analysis of factors associated with ﬁnal VAS scores showed that
baseline VAS scores affected ﬁnal VAS scores (p < 0.0001). CON-
CLUSION: There appears to be no difference in quality of life for
patients on 90Y-ibritumomab tiuxetan as compared to those in
control arm as measured by EORTC QLQ C-30 and EQ-5D
questionnaires. 90Y-ibritumomab tiuxetan prolongs PFS without
impacting the health-related quality of life of patients.
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OBJECTIVE: To quantify the impact of disease and its treatment
on patient-reported well-being, it is important to consider the
patient’s economic circumstances. This study explored the rela-
tionship between annual household income and health-related
psychological well-being among insured, long-term (>ﬁve years)
colorectal cancer (CRC) survivors with and without permanent
intestinal stomas. METHODS: This is a secondary analysis of
data collected as part of an NCI-funded study of health-related
quality of life (HRQOL) among CRC survivors, in which 681
respondents (52% response rate) completed a survey instrument
that included the modiﬁed City of Hope Quality of Life (mCOH-
QOL)–Ostomy questionnaire, SF-36 v2, and socio-demographic
items. Of these, 588 subjects provided income data and were
included in this analysis. The mCOH-QOL–Ostomy is based on
a four-dimension model of HRQOL (physical, psychological,
social, and spiritual well-being). For this analysis, the dependent
variable was the psychological well-being (PWB) score. Hierar-
chical linear regression was used to explore the unique contribu-
tion of income to the total variance of PWB over and above the
model that included the following independent variables: self-
reported physical health (SF-36v2 PCS), co-morbidity (Charlson-
Deyo), age, sex, race/ethnicity, education, partnered status, and
presence of an ostomy. RESULTS: After accounting for the pro-
portion of variance in PWB explained by the other independent
variables, the additional variance explained by income was sig-
niﬁcant (R2 increased from 0.228 to 0.250; p = 0.006). When
compared to those in the highest household income category
(>$100,000), subjects in the lowest income category (<$5000)
had a clinically meaningful 0.82 point lower PWB score on the
11-point scale. Signiﬁcant positive predictors of PWB were PCS
score, age, and absence of an ostomy. CONCLUSION: Although
the study design does not allow causal inference, these results
demonstrate a signiﬁcant relationship between income and PWB
that merits further consideration when attempting to interpret
patient-reported outcomes, particularly HRQOL.
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OBJECTIVE: To provide qualitative data on the men’s experi-
ence, impact and relative importance of hot ﬂushes as a result of
prostate cancer therapies, with an emphasis on gonadotropin-
releasing hormone (GnRH) agonists. METHODS: A qualitative
study applying a non-probabilistic purposive sampling strategy.
Participants were over 50 years old with histologically conﬁrmed
adenocarcinoma of the prostate, had recently initiated (6
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months ago) and were receiving GnRH with or without anti-
androgen, and had recent experience of hot ﬂushes as a result of
their therapy. A content and thematic analysis was conducted to
identify themes and categories that centred on particular phrases,
incidents and types of behaviour. RESULTS: Participants (n = 12)
aged 58–82, diagnosed on average for 5 years, receiving GnRH
agonists (100.0% Lupron, 40.0% Casodex, 20.0% Zometa)
were interviewed. The ﬁrst hot ﬂush usually occurred within 2
weeks of GnRH treatment. Participants experienced widely dif-
fering hot ﬂush event frequency and severity; from 8–10 events in
24 hours to one in 2–3 weeks. Events lasted 2 minutes to one
hour, and occurred at different times. Analyses identiﬁed that hot
ﬂushes were most commonly described in terms of ‘sweating’,
‘burning up’, and ‘perspiring’. Those who had more severe
ﬂushes also described ‘dizziness’, ‘weakness’, and ‘nausea’. Par-
ticipants found their hot ﬂush experience generally distressing
e.g. felt scared, anxious, annoyed, confused, irritated, worried.
Hot ﬂushes impacted men’s lives e.g. sleep problems, needing to
stop activities, resting, taking a cold shower. However, most
considered the hot ﬂush experience in the context of their overall
condition, some reported getting used to the experience over time
and adopting varies coping strategies. CONCLUSION: Hot ﬂush
descriptions reﬂect those previously reported in the literature,
provide additional depth to the experience from the patient’s
perspective and will inform the development of health states for
utility assessment.
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OBJECTIVE: Hodgkin’s lymphoma (HL) signiﬁcantly impacts
the health related Quality of Life (HRQoL) of patients. Treated
patients often report increased stress, fatigue, nausea, sexual
dysfunction, decreased social and emotional function, and
vocational limitations; however few studies have assessed these
domains. This review summarizes the impact of HL on hrQoL
and recommends which HRQoL constructs should be assessed in
the clinic and in clinical trials. METHODS: A systematic review
of the literature was conducted in order to better understand the
impact of HL and its treatments on HRQoL. The identiﬁed
articles were reviewed for references to HRQoL and speciﬁc tools
to assess these constructs. The major impacts of the disease and
treatment effects are compared across tools assessing these
domains. RESULTS: Some 30 published studies assessing hrQoL
in patients with HL were identiﬁed. In these 30 articles over 20
instruments were used to assess HRQoL. The most common
cancer-speciﬁc instruments employed were the EORTC QLQ-30
and various fatigue scales. No HL speciﬁc instrument was iden-
tiﬁed as being widely used. Tables summarizing the domains
covered by each instrument are provided. The EORTC and
FACT-Lym appear to provide the best coverage of relevant
HRQoL domains, however, using more than one instrument is
necessary to capture all relevant domains. CONCLUSION:
Although HL signiﬁcantly impacts HRQoL very few studies have
collected this data in a comprehensive manner. This work reviews
the literature on the HRQoL in patients with HL and provides
insights regarding the key set of HRQoL constructs that should
be assessed in the clinic and in clinical trials to best characterize
the impact of HL and treatment. Although the FACT-Lym pro-
vides good coverage of HRQoL domains in HL, additional vali-
dation work is needed to ensure the reliability and validity of the
tool in this population.
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OBJECTIVE: To estimate general public preference-based utili-
ties for standardized health states that include common responses
and toxicities observed during treatment of advanced melanoma.
METHODS: A cross-sectional study was used to elicit standard
gamble utilities for melanoma in the UK and Australia. Health
states included partial response (PR), stable disease (SD) and
progressive disease (PD). Common grade I/II toxicities (occurring
in >10% of patients) were abstracted from the literature for
dacarbazine, temozolomide, interleukin-2, fotemustine, and
interferon alpha2b. These may also apply for ipilumumab, a
developmental immunotherapy. Health state descriptions were
based on WHO response deﬁnitions, Common Toxicity Criteria
for Adverse events v3, and feedback from ﬁve clinical experts and
three quality-of-life researchers. RESULTS: Utilities were elicited
from 110 participants in the UK (n = 64) and Australia (n = 56).
Mean utilities estimated (for UK vs. Australian respondents)
were as follows: PR (0.85 vs. 0.89); SD (0.77 vs. 0.80); PD (0.59
vs. 0.44); and best supportive care (0.59 vs. 0.44). Utility decre-
ments associated with the toxicities were: hair loss (-0.03); skin
reaction (-0.03 vs. -0.08); diarrhea (-0.06 vs. 0.12); toxicity,
but indication that treatment may be working (-0.06 vs. -0.08);
nausea/vomiting (-0.07 vs. -0.13); ﬂu-like syndrome (-0.09 vs.
-0.13); stomatitis (-0.10 vs. -0.15); 1-day out/inpatient care for
grade 3/4 toxicity (-0.11 vs. -0.15); symptomatic melanoma
(-0.11 vs. -0.22); and hospitalization for grade 3/4 toxicity
(-0.13 vs. -0.22). CONCLUSION: The development process for
these standardized health states for advanced melanoma can
serve as a model for developing disease-speciﬁc health states
that incorporate both intended treatment responses and adverse
events. PR and SD are preferred, and symptomatic melanoma
and hospitalization for toxicity yield the highest disutilities. The
method of decrementing utility values by subtracting toxicity
utility weights holds promise for assigning utilities to serious
diseases treated with toxic therapies.
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OBJECTIVE: There is limited experience with patient-reported
health status and health-related quality of life (HRQL) in survi-
vors of cancer in childhood in low-income countries. The purpose
of this study was to collect these measurements in Brazil, test
hypotheses about differences among diagnostic groups, and
compare the results with those from other countries in an overall
assessment of the construct validity of the HUI3. METHODS:
Survivors were eligible if: diagnosed with cancer in childhood;
attending the long-term follow-up clinic for one treatment center;
at least 8 years off therapy; cancer free, literate; and at least
13 years of age. Health status measurements were collected in
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